arrow
A

Anna Koumarianou

attikon university general hospital
H指数:30
被引数:2,996

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Peripheral T-Cell Receptor β Repertoire Dynamics Correlate with Response to Anti-PD-L1 Therapy in Non-Small Cell Lung Cancer

外周T细胞受体β库动力学与非小细胞肺癌对PD-L1抑制剂的应答相关

Cancers
IF4.4
2026-07-280
OA
Association of Driver Oncogenic Alterations with SUVmax, Preoperative Serum Calcium, and Smoking Status in Surgically Resected Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study

驱动基因突变与非小细胞肺癌术后SUVmax、术前血清钙水平及吸烟状况的相关性:一项回顾性单中心研究

2026-05-280
OA
Germline Genetic Testing in Breast and Gynecologic Cancers: Evaluating Age at Diagnosis as a Determinant

乳腺癌和妇科癌症中的胚系遗传检测:评估诊断年龄作为决定因素

Cancers
IF4.4
2026-05-100
OA
Real-World Neoadjuvant Systemic Therapy Utilization and Treatment Patterns in Patients with Early-Stage or Locally Advanced Triple-Negative Breast Cancer in Greece—The TRINITY Study

真实世界中希腊早期或局部晚期三阴性乳腺癌患者新辅助全身治疗的应用及治疗模式—TRINITY研究

2025-12-170
OAAI
Real-World Toxicity and Effectiveness Study of Abemaciclib in Greek Patients with Hormone Receptor-Positive-Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Multi-Institutional Study

希腊激素受体阳性-人表皮生长因子受体2阴性乳腺癌患者中阿贝西利片的真实世界毒性和有效性研究:一项多中心研究

2025-08-200
PRE
Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final Outcome, Immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study.

插入式阿维鲁唑胺联合铂类为基础的化疗在广泛期小细胞肺癌患者中的应用(PAVE):一项多中心Hellenic Cooperative Oncology Group II期研究的最终结果、免疫表型分析和生物标志物分析。

2025-07-250
OAAI
The Benefits of comprehensive NGS Panels using Liquid Biopsy in Breast Cancer

综合NGS Panels通过液体活检在乳腺癌中的优势

BREAST
IF7.9
2025-02-010
OAAI
The prognostic role of Ki-67 in relation to Oncotype DX Recurrence Score

Ki-67在Oncotype DX复发评分中的预后作用

BREAST
IF7.9
2025-02-010
OAAI
Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force
2024-12-091
OA
Polygenic Risk Score (PRS) Combined with NGS Panel Testing Increases Accuracy in Hereditary Breast Cancer Risk Estimation

多基因风险评分 (PRS) 与NGS小组测试相结合,可提高遗传性乳腺癌风险评估的准确性

2024-08-210
OAAI
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force
2024-05-163
PRE
Real-world data on the safety and efficacy of trastuzumab deruxtecan and sacituzumab govitecan in patients with advanced breast cancer: the experience of the Hellenic Cooperative Oncology Group
2024-03-010
PRE
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes

早期乳腺癌患者采用环磷酰胺与表柔比星序贯、密集给药,随后序贯多西他赛辅助治疗的十年临床疗效、毒性和依从性:一项由希腊肿瘤协作组开展的观察性研究(HE 10/10),并同步探讨肿瘤浸润淋巴细胞的临床意义

BREAST
IF7.9
2024-02-014
OAAI
Use and perceived utility of [18F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022
2023-12-147
PRE
Testing HR+ / HER2-patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)
2023-10-010
OA